Dr Robert P. Giugliano is a Senior Investigator with the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Staff Physician in the Cardiovascular Division at the Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, Boston, USA. He graduated summa cum laude and phi beta kappa from Dartmouth College, and received his medical degree at Harvard Medical School. Dr Giugliano completed his internship, residency and chief residency at Cedars-Sinai Medical Centre, Los Angeles, USA, and then returned to Boston as a Cardiology Fellow at the Massachusetts General Hospital, USA.  

His research interests include novel lipid-lowering therapies, antithrombotic therapies for atrial fibrillation and acute coronary syndromes (ACS), and the assessment of outcomes in patients with ACS. Dr Giugliano has authored more than 360 original articles and 250 reviews/editorials/book chapters. He is the Founding Scientific Advisor and Editor-in-Chief for MD Conference Express, Co-Editor-in-Chief of Cardiology and Therapy, and serves on editorial boards for Circulation, The American Heart Journal, Clinical Cardiology, Cor et Vasa, Hospital Practice, Cardiovascular Therapeutics and Clinical Pathways in Cardiology. 

Dr Giugliano is the Principal TIMI Investigator for over a dozen clinical trials including the VESALIUS-CV trial with evolocumab, ENGAGE AF-TIMI 48 trial with edoxaban, and Executive Committee member of several additional trials including the IMPROVE-IT (ezetimibe), FOURIER (evolocumab), AZALEA-TIMI 71 (abelacimab) and CORE trials (olezarsen) trials. 

Dr Robert P. Giugliano has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Disclosures in the past 36 Months

Clinical trials / Research support
1. Amgen
2. Anthos Therapeutics
3. Daiichi Sankyo
4. Ionis
5. Novartis

Honoraria for Lectures / CME Programs
1. Academy Continued Healthcare Learning
2. Amgen
3. Big Sky Cardiology
4. CADECI
5. Centrix
6. Daiichi Sankyo
7. Dr. Reddy's Laboratories
8. Korean Heart Rhythm Society
9. Medical Education Resources (MER)
10. Medcon
11. Menarini
12. Radcliffe Med Ed
13. Servier
14. SHAKEHEART
15. Shanghai Medical Network Technology
16. SUMMEET

Consultant
1. Artivion, Inc.
2. Beckman Coulter, Inc.
3. Celecor
4. Daiichi Sankyo
5. Gilead
6. Inari
7. Inventiva
8. Medpace, Inc.
9. Novartis
10. Parexel
11. Perosphere
12. PhaseBio
13. Samsung
14. Scleroderma Research Foundation, Inc
15. Syneos Health